Compare Ascendis Pharma A/S (ASND) vs Seagate Technology Holdings PLC (STX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Seagate Technology Holdings PLC — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Seagate Technology Holdings PLC trades at $877.58 (market cap $205.97B). The key difference: Seagate Technology Holdings PLC is far larger — about 11.6× Ascendis Pharma A/S's market cap, and Seagate Technology Holdings PLC pays a 0.33% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | STX | |
|---|---|---|
Market Cap | $17.74B | $205.97B |
Sector | Health | Technology |
52-Week High | $277.18 | $1.09K |
52-Week Low | $163.32 | $146.59 |
Enterprise Value | $18.11B | $209.00B |
Dividend Yield | — | 0.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Seagate Technology (STX) trades at $910.34, up 2.28% with strong momentum driven by AI infrastructure demand. The stock shows impressive fundamental improvement with revenue growth from $6.6B to $9.1B and net income surging to $1.47B in 2025. Technical indicators are mixed with bullish moving averages but neutral oscillators, while analyst sentiment remains positive with a $981.43 consensus target representing 7.8% upside potential.
STX presents compelling growth prospects as AI-driven storage demand accelerates, supported by three consecutive earnings beats and expanding margins. Key risks include high valuation multiples (P/E 86.37), significant debt levels, and competitive pressures in the storage market. The company's positioning in AI infrastructure and strong institutional support suggest continued upside potential despite elevated valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Seagate Technology Holdings PLC
Seagate is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital
Read more on STX →
